Cargando…

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?

Detalles Bibliográficos
Autores principales:	Ahmed, Abdulla, Ahmed, Salaheldin, Rådegran, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689888/ https://www.ncbi.nlm.nih.gov/pubmed/38045096 http://dx.doi.org/10.1002/pul2.12314

Ejemplares similares

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
por: Ahmed, Salaheldin, et al.
Publicado: (2021)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
por: Kania, Kriss, et al.
Publicado: (2022)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension
por: Engel Sällberg, Adam, et al.
Publicado: (2023)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next>
por: Simarro, Pere P, et al.
Publicado: (2008)

Gene × Environment Interaction in Developmental Disorders: Where Do We Stand and What’s Next?
por: Esposito, Gianluca, et al.
Publicado: (2018)

The Evolution of Reverse Total Shoulder Arthroplasty—Where Do We Stand and What Comes Next?
por: Bauer, Stefan, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

The gut microbiota in osteoarthritis: where do we stand and what can we do?
por: Hao, Xiaoxia, et al.
Publicado: (2021)

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
por: Lucarelli, Enrico, et al.
Publicado: (2023)

Moving Average-Based Multitasking In Silico Classification Modeling: Where Do We Stand and What Is Next?
por: Halder, Amit Kumar, et al.
Publicado: (2022)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

New therapies for spinal muscular atrophy: where we stand and what is next
por: Antonaci, Laura, et al.
Publicado: (2023)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Plasma Biomarkers for Clinical Assessment of Bone Mineral Density in Heart Transplanted Patients—A Single-Center Study at Skåne University Hospital in Lund
por: Löfdahl, Eveline, et al.
Publicado: (2022)

Translating Tolerogenic Therapies to the Clinic – Where Do We Stand and What are the Barriers?
por: Cobbold, Stephen P., et al.
Publicado: (2012)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Genetics of Keratoconus: Where Do We Stand?
por: Abu-Amero, Khaled K., et al.
Publicado: (2014)

Cricoid pressure: Where do we stand?
por: Bhatia, Nidhi, et al.
Publicado: (2014)

Combating Malaria: Where do We Stand?
por: Coats, Mamie T
Publicado: (2016)

Where Do We Stand in Preventive Medicine?
por: Robertson, Wm.
Publicado: (1921)

Bevacizumab in Glaucoma: Where do We Stand?
por: Khanna, Anjani
Publicado: (2012)

Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bifsvq5d1jgmnjirv830dsqag2